Effects of Oxygen Status on Hypoxia Inducible Factor 1-α and Inflammation. A Pilot Proof of Principle Study.

NCT ID: NCT01889823

Last Updated: 2015-03-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It has been shown in in vitro and animal models that hypoxia can have pro-inflammatory effects and hyperoxia can have anti-inflammatory effects. The pro-inflammatory effect could be the result of activation of Hypoxia Inducible Factor, a transcription factor that is known to activate many cell systems aimed at cell survival, including the inflammatory response. The anti-inflammatory effects of hyperoxia could be the annihilation of Hypoxia Inducible Factor, but also a decrease in inflammation due to oxygen toxicity resulting in a decrease in clearance of pathogens. These effects have been sparsely studied in humans. Therefore, we hypothesize that hypoxia results in an increase in Hypoxia Inducible Factor in circulating leukocytes and increases inflammatory reactions, whereas hyperoxia decreases these reactions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypoxia Hyperoxia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hypoxia

Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.

Group Type EXPERIMENTAL

Hypoxia

Intervention Type OTHER

Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.

Hyperoxia

Subjects will be breathing 100% of oxygen

Group Type EXPERIMENTAL

Hyperoxia

Intervention Type OTHER

Subjects will be breathing 100% oxygen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hypoxia

Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.

Intervention Type OTHER

Hyperoxia

Subjects will be breathing 100% oxygen

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 and ≤35 yrs
* Male
* Healthy

Exclusion Criteria

* Use of any medication
* Smoking
* History, signs or symptoms of cardiovascular disease
* History of atrial or ventricular arrhythmia
* (Family) history of myocardial infarction or stroke under the age of 65 years
* Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block
* Hypertension (defined as RR systolic \> 160 or RR diastolic \> 90 mmHg)
* Hypotension (defined as RR systolic \< 100 or RR diastolic \< 50 mmHg)
* Renal impairment (defined as plasma creatinine \>120 μmol/l)
* Liver enzyme abnormalities alkaline phosphatase\>230 U/L and/or ALT\>90 U/L
* Medical history of any obvious disease associated with immune deficiency
* CRP \> 20 mg/L, WBC \> 12x109/L, or clinically significant acute illness, including infections, within 4 weeks before endotoxemia day
* Participation in a drug trial or donation of blood 3 months prior to the experiment
* Pre-existent lung disease or asthma
* Use of recreational drugs within 21 days prior to experiment day
* Visit to altitude \>1500m within 4 weeks prior to the experiment
* Air travel with flight time over 3 hours within 4 weeks prior to the experiment
* History of acute mountain sickness
* Recent hospital admission or surgery with general anaesthesia (\<3 months)
* Claustrophobia
* Feelings of discomfort during a 10 minute test wearing the transparent respiratory helmet at the screening visit
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Radboud University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Peter Pickkers

Prof. dr. P. Pickkers

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dorien Kiers, MD

Role: PRINCIPAL_INVESTIGATOR

Intensive Care Medicine, Radboud University Nijmegen Medical Centre

Peter Pickkers, MD,PhD

Role: STUDY_DIRECTOR

Intensive Care Medicine, Radboud University Nijmegen Medical Centre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Intensive Care Medicine, Radboud University Nijmegen Medical Centre

Nijmegen, Nijmegen, Gelderland, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OX1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Imaging Regional Lung Defect Severity
NCT01640288 COMPLETED PHASE1/PHASE2
Comparison of 133Xe Scintigraphy With 19F MRI
NCT03532334 WITHDRAWN EARLY_PHASE1
Biomarker in Lung Diseases
NCT00989846 UNKNOWN